B cell suppression in newborn following treatment of pregnant diffuse large B-cell lymphoma patient with rituximab containing regimen

Indian J Pediatr. 2014 Oct;81(10):1092-4. doi: 10.1007/s12098-013-1336-9. Epub 2014 Feb 22.

Abstract

Non-Hodgkin lymphoma associated with pregnancy is rare. Rituximab based chemotherapy is now considered the standard of care and considered safe for the treatment of diffuse large B-cell lymphoma (DLBCL) during pregnancy but little is known about its safety profile on the fetus. A 32 y primigravida was diagnosed as DLBCL at 20 wk of gestation. She received rituximab containing chemotherapy with successful pregnancy outcome. Though the baby was absolutely healthy, B-cell was totally absent in the cord blood.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • B-Lymphocytes / drug effects*
  • Female
  • Fetal Blood / cytology*
  • Humans
  • Infant, Newborn
  • Lymphocyte Count
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Pregnancy
  • Pregnancy Complications, Neoplastic / drug therapy*
  • Rituximab / adverse effects
  • Rituximab / therapeutic use*

Substances

  • Antineoplastic Agents
  • Rituximab